Stimulant supplement

Caffeine Anhydrous

Reviews give caffeine's elimination half-life as 2.5 to 10 hours; the app lists 5.5 hours.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Caffeine Anhydrous after one dose: 50% at ~5.5 h, 25% at 11 h, 12.5% at 16.5 h.

Drawn from the half-life in the app's model, ~5.5 h. The model's figures

Caffeine anhydrous is listed in the app as a stimulant supplement taken by mouth, graded by the app as strong evidence. A US over-the-counter tablet label lists caffeine 200 mg per tablet with the purpose "Alertness Aid".2 That label gives the use as helping "restore mental alertness or wakefulness when experiencing fatigue or drowsiness".2 The FDA's consumer update says caffeine "can be part of a healthy diet for most people" and cites 400 milligrams a day for most adults as an amount "not generally associated with negative effects".3 The same sentence continues that "too much of it can have negative effects and large amounts may pose a danger", and the FDA adds that "too much" can vary from person to person.3 The same FDA page says there is "wide variation in both how sensitive people are to the effects of caffeine and how fast they eliminate it from the body".3 In the trials below, Lara and colleagues gave caffeine in capsules, Drake and colleagues in pills and Trexler and colleagues in a flavoured drink, and Trexler and colleagues name the powder they used "caffeine anhydrous".9,8,7

2

How it works

Magkos and Kavouras, in a 2005 review in Critical Reviews in Food Science and Nutrition, call blockade of adenosine receptors "probably" the most physiologically relevant mechanism of caffeine.1 Cappelletti and colleagues, Current Neuropharmacology, 2015, write that caffeine "blocks adenosine receptors, mainly A1 and A2A subtypes, competitively antagonizing their action and causing an increased release of dopamine, noradrenalin, and glutamate".4 The same review states that the mobilisation of intracellular calcium and the inhibition of phosphodiesterases "require higher doses of caffeine, unlikely to be obtained with the common daily dietary sources of caffeine".4 Magkos and Kavouras list those further actions, including "non-selective adenosine receptor antagonism", among effects seen in in vitro studies, and say not all of them seem to account for the effects seen in people.1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~5.5 h
Bioavailability
99%
Typical dose
100–400 mg/dose
Route
Oral
Time to peak
~0.75 h

The second column holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~5.5 hElimination half-lives of 2.5 to 10 hours in a 2005 review, and 2 to 12 hours in a 2015 review; the 2015 review attributes the range mainly to inter-individual variability in absorption and metabolism, and the 2005 review notes considerable inter-individual variability in the handling of caffeine by the body1,4
Bioavailability99%Described as "rapidly and completely absorbed" from the gastrointestinal tract, with negligible pre-systemic metabolism; the sources read give no percentage1,4
Time to peak~0.75 h (45 min)Maximum plasma concentration "after 30-60 minutes from consumption", with reports between 15 and 120 minutes4
EliminationNot in the appCYP1A2 accounts for about 95% of caffeine clearance; 0.5% to 2% of ingested caffeine is excreted unchanged in urine, and less than 5% in a second review4,5,1
MetabolitesNot in the appDemethylation gives mostly paraxanthine (84%), then theobromine (12%) and theophylline (4%)4

Cappelletti and colleagues report that smokers have "a metabolism rate that is almost twice the one of nonsmokers" and that pregnancy "decreases the clearance and excretion of caffeine".4 Kaplan and colleagues, Journal of Clinical Pharmacology, 1997, gave 12 healthy volunteers oral placebo, 250 mg and 500 mg of caffeine as single doses and reported that "Caffeine kinetics were nonlinear, with clearance significantly reduced and elimination half-life prolonged at the 500-mg compared to the 250-mg dose".6 The app lists a single half-life of 5.5 hours; its figure falls inside the ranges above, and the sources read show it moving with dose and between people.6,1

4

Human studies

The table lists the trials and reviews with a quotable result; three are described further below.

Table 4.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Kaplan and colleagues, J Clin Pharmacol 19976Randomised, double-blind, single-dose crossover; NIH grants612 healthy volunteers6Oral placebo, 250 mg or 500 mg, single doses6250 mg improved digit symbol substitution and tapping speed against placebo, 500 mg gave less enhancement; unpleasant effects (tension, nervousness, anxiety, nausea, palpitations and others) after 500 mg exceeded those after 250 mg6
Trexler and colleagues, Eur J Sport Sci 20167Randomised, double-blind (partly blinded, coffee taste), three groups; funded by the NSCA Foundation754 resistance-trained males who completed (56 enrolled)7300 mg caffeine anhydrous, 303 mg caffeine as coffee, or placebo, 30 min before one test session7Neither coffee nor caffeine anhydrous improved strength outcomes more than placebo; both attenuated sprint power reductions to a similar degree7
Drake and colleagues, J Clin Sleep Med 20138Randomised, double-blind, double-dummy, placebo-controlled Latin square, in the home; funded by Zeo Inc812 healthy normal sleepers who completed (16 screened, 4 excluded for protocol violations)8400 mg caffeine in pill form at 6, 3 or 0 h before bedtime, or placebo; one night per condition8Total sleep time on the portable monitor fell by 1.1 to 1.2 hours at each time against placebo; the diary showed a 41 min fall at 6 h that approached significance (p = 0.08)8
Lara and colleagues, PLoS One 20199Randomised, double-blind, placebo-controlled crossover; no specific funding911 healthy active participants, light caffeine consumers93 mg/kg/day caffeine or placebo in capsules for 20 consecutive days9Peak cycling power in the incremental test rose by about 4.0 ±1.3% against placebo for the first 15 days, then the effect lessened; the effect was largest on day 19
Watson and colleagues, Br J Clin Pharmacol 200210Randomised, double-blind crossover; funding not stated in the article text read1012 healthy volunteers10200 mg caffeine or placebo twice daily for 1 week, then a 200 mg caffeine challenge10Middle cerebral artery blood velocity fell in both conditions, more in the caffeine-naive condition; tense mood was higher at baseline after regular caffeine; cognitive performance was not affected by previous caffeine exposure10
Grgic and colleagues, Br J Sports Med 202011Umbrella review of meta-analyses; competing interests none declared1111 reviews with 21 meta-analyses; most individual studies in young men11Caffeine ingestion; route and doses not stated in the record read11Caffeine was ergogenic for aerobic endurance, muscle strength, muscle endurance, power, jumping performance and exercise speed, though not all analyses gave a definite direction on the 95% prediction interval; quality of evidence was generally categorised as moderate, with some low to very low11
Gardiner and colleagues, Sleep Med Rev 202312Systematic review and meta-analysis; no conflicts of interest declared1224 included studies12Caffeine against control before night-time sleep; doses varied by study12Total sleep time lower by 45 min, sleep efficiency by 7%, sleep onset latency longer by 9 min, wake after sleep onset longer by 12 min12
Wikoff and colleagues, Food Chem Toxicol 201713Systematic review of adverse-effect literature published 2001 to June 201513381 studies met criteria for the five outcomes in healthy adults, pregnant women, adolescents and children13Intakes compared with 400 mg/day for adults, 300 mg/day in pregnancy, 2.5 mg/kg/day for children and adolescents13Up to 400 mg/day in healthy adults generally not associated with overt adverse cardiovascular, behavioural, reproductive and developmental, acute or bone effects13

Deeper analysis: Trexler, caffeine anhydrous against coffee

Trexler and colleagues at the University of North Carolina at Chapel Hill, European Journal of Sport Science, 2016, compared caffeine anhydrous with a caffeine-matched coffee and a placebo before strength and sprint testing.7 Each of three groups of 18 received 300 mg caffeine anhydrous, 303 mg caffeine as instant coffee, or a placebo drink 30 minutes before one repeated testing session, after a baseline session at least 48 hours earlier.7 Participants had a mean habitual caffeine intake of 32.9 ± 59.6 mg/day, and the study excluded habitual intake above 800 mg per day.7 The leg press one-repetition maximum improved more with coffee than with caffeine anhydrous (p = .04), and neither differed from placebo.7 Bench press one-repetition maximum, bench press repetitions to fatigue and leg press repetitions to fatigue showed no significant interactions.7 There were no sprint by treatment interactions for peak power or total work, while confidence intervals showed a significant improvement in sprint 1 total work for caffeine anhydrous only.7 The authors conclude that "Caffeine anhydrous does not appear to improve performance more than coffee".7 They note that improvement in the placebo group on strength tests suggests "a learning effect or a placebo effect".7 Their stated limitations include "the provision of a flat dose of caffeine (300 mg) rather than scaling the dosage to bodyweight", and low habitual intake, which "may limit generalizability to heavy caffeine users".7 The funders were the National Strength and Conditioning Association Foundation and the National Center for Advancing Translational Sciences, and the anhydrous powder came from the supplier Smart Powders.7 The article text read has no competing-interest statement and reports no adverse events from the caffeine.7

Deeper analysis: Drake, caffeine and sleep

Drake and colleagues at the Henry Ford Hospital Sleep Disorders and Research Center, Detroit, reported in the Journal of Clinical Sleep Medicine in 2013 a home study of 400 mg of caffeine taken 0, 3 or 6 hours before habitual bedtime.8 Twelve participants (6 women, 6 men, aged 19 to 48) with a mean baseline caffeine intake of 115 ± 169 mg/day completed all four nights.8 On the portable monitor, "The different caffeine administration times (0, 3, or 6 h before bed) did not produce differential sleep disruption among the 3 active caffeine conditions".8 Only the 3 h condition significantly prolonged latency to persistent sleep (+17.2 min), and wake time during sleep rose significantly at 6 h (+8 min) and 3 h (+27.6 min).8 In the sleep diary, "No significant effects were observed for WTDS, SE, or sleep quality", and the 41 minute fall in total sleep time at 6 hours approached but did not reach significance.8 The authors list limitations: plasma concentrations were not obtained, the number of subjects was small, intermittent exposure "precludes us from making any conclusions regarding possible tolerance", and the authors call the sleep-stage results "preliminary".8 They also write that "the use of young/middle-age participants with moderate habitual caffeine use limits the generalizability of the findings".8 Funding came from an investigator-initiated grant from Zeo Inc, whose sleep monitor was used; the disclosure states that one author was Vice President of Scientific Affairs at Zeo from April 2007 to April 2010 and no longer holds a financial interest, and that the first author has received funding from Merck, Teva and Zeo.8 The article text read reports no adverse events outside the sleep outcomes.8 Gardiner and colleagues pooled 24 studies in Sleep Medicine Reviews in 2023, and their calculation for coffee of 107 mg per 250 mL was 8.8 hours before bedtime to avoid reduced total sleep time, against 13.2 hours for a pre-workout serve of 217.5 mg.12 In that analysis, light sleep (N1) rose by 6.1 min and deep sleep (N3 and N4) fell by 11.4 min.12

Deeper analysis: Lara, tolerance over 20 days

Lara and colleagues reported in PLoS One in 2019 a crossover trial in which 11 healthy active participants took 3 mg/kg/day of caffeine or placebo daily for 20 consecutive days, tested three times a week 45 minutes after the capsule.9 The caffeine was 100% purity powder in capsules; participants refrained from dietary caffeine for the month before and during the experiment.9 Peak power in the Wingate test rose by about 4.9 ±0.9% on days 1, 4, 15 and 18, and in both tests the effect was highest on day 1 and then progressively decreased.9 On day 11, when testing came before the capsule, caffeine Wmax and Wingate peak power fell to a similar value to the placebo trial, and neither perceived muscle power nor blood lactate after the Wingate test differed significantly between caffeine and placebo.9 The authors write that "These results show a continued ergogenic effect with the daily ingestion of caffeine for 15-18 days; however, the changes in the magnitude of this effect suggest progressive tolerance".9 They also state that "caffeine still exerted small-to-moderate improvements on physical performance after 20 days of consecutive administration".9 Their stated limitations include that the 20-day length cannot show whether greater tolerance would occur later, that only one moderate dose was used, and that "we did not obtain blood samples during the ingestion protocols to determine plasma caffeine concentration".9 The authors declared no competing interests and received no specific funding.9 Adverse events were not reported as an outcome in the article text read.9 Watson and colleagues, in the British Journal of Clinical Pharmacology in 2002, concluded that "tolerance is incomplete with respect to both peripheral or central effects of caffeine".10 The authors add that tolerance was not demonstrated in performance or in improvements in positive aspects of mood, and the PubMed record lists the publication type as Research Support, Non-U.S. Gov't without naming a funder.10

5

Doses reported in studies and on labels

The app lists a typical dose of 100 to 400 mg per dose; the US tablet label lists 200 mg per tablet, and the FDA cites 400 milligrams a day for most adults, a daily figure.2,3 The US tablet label gives its directions for adults and children 12 years and over as "take 1 tablet not more often than every 3 to 4 hours", marks it "For occasional use only" and lists "in children under 12 years of age" and "as a substitute for sleep" under "Do not use".2

Table 5.1Doses reported in studies and on labels9 rows
SourceDoseRoute and lengthPeople and comparatorWhat is reported
US tablet label2200 mg per tabletOral tablet; label spacing of 3 to 4 hours at the shortestAdults and children 12 and over, per the label directionsPurpose "Alertness Aid"2
FDA consumer update3400 mg a dayDaily total from all sourcesMost adults"Not generally associated with negative effects"; per day, not per dose3
FDA consumer update3Around 1,200 mgRapid consumptionNot specifiedThe FDA estimates toxic effects, like seizures, can be observed3
Wikoff and colleagues 201713400 mg/day; 300 mg/day; 2.5 mg/kg/dayDaily intakeHealthy adults; healthy pregnant women; children and adolescentsComparator intakes; evidence supports up to 400 mg/day in healthy adults as generally not associated with overt adverse cardiovascular, behavioral, reproductive and developmental, acute or bone effects, and up to 300 mg/day in healthy pregnant women as generally not associated with adverse reproductive and developmental effects; limited data were identified for child and adolescent populations13
Kaplan 19976250 mg and 500 mgOral, single dose12 healthy volunteers; placeboMore unpleasant effects and less performance enhancement at 500 mg than 250 mg6
Trexler 20167300 mg anhydrous (3–5 mg/kg)Oral drink, 30 min before testing54 resistance-trained males; coffee 303 mg and placeboNo strength gain over placebo; sprint power reductions attenuated7
Drake 20138400 mgOral pill, 0, 3 or 6 h before bed, one night each12 healthy normal sleepers; placeboObjective total sleep time lower by 1.1 to 1.2 hours at each time8
Lara 201993 mg/kg/day, about 200 mg/day in these participantsOral capsule, 20 consecutive days11 healthy active participants; placeboPeak power effect largest on day 1, still small-to-moderate at day 209
Watson 200210200 mg twice daily, then 200 mg challengeIngestion, 1 week12 healthy volunteers; placeboMiddle cerebral artery blood velocity fell in both conditions, more in the caffeine-naive one; the authors conclude tolerance is incomplete for peripheral and central effects, and write that tolerance was not demonstrated in performance or in improvements in positive aspects of mood10

The app's high end of 400 mg per dose matches the FDA's 400 mg figure for a whole day, so the two are on different bases.3

The FDA consumer update lists signs of too much caffeine: increased heart rate, heart palpitations, high blood pressure, insomnia or sleep disruptions, anxiety, jitters, upset stomach, nausea and headache.3 The tablet label warns that "too much caffeine may cause nervousness, irritability, sleeplessness, and occasionally, rapid heartbeat".2 The same label adds "If pregnant or breast-feeding, ask a health professional before use".2 In the Kaplan crossover, tension, nervousness, anxiety, excitement, irritability, nausea, palpitations and restlessness after 500 mg exceeded those after 250 mg.6 In the Watson trial, "Mood was adversely affected by regular caffeine consumption", with tense mood higher at baseline after a week of regular dosing.10 The FDA says caffeine withdrawal "isn't considered dangerous but can be unpleasant".3 Wikoff and colleagues, whose author list includes several people affiliated with the consultancy ToxStrategies and whose PubMed record has no funding statement, concluded that up to 400 mg a day in healthy adults is generally not associated with the overt effects they reviewed.13 The review notes "Limited data were identified for child and adolescent populations".13 The FDA page attributes a 2017 systematic review to the Institute for the Advancement of Food and Nutrition Sciences and says it "confirmed the safety of the 400 milligrams a day level for most adults".3 For pure and highly concentrated products the FDA says they "can have serious health consequences, including death".3

The 2026 WADA Prohibited List names caffeine among substances that "are included in the 2026 Monitoring Program and are not considered Prohibited Substances".14 The FDA says food companies are responsible for the safety of caffeine in their products, and that "All packaged foods are required to list caffeine in the 'list of ingredients' when it is added to products as a stand-alone ingredient".3 The FDA also says that in the mid-2010s pure or highly concentrated caffeine products emerged, that it took action, and that "some products containing pure and highly concentrated caffeine remain on the market".3 The US caffeine 200 mg tablet label lists caffeine as the active ingredient in each tablet, with the purpose "Alertness Aid".2

8

Storage and handling

The tablet label says "store at room temperature" and "avoid excessive heat (greater than 100°F) or humidity".2

The sources read state complete absorption but give no percentage for oral bioavailability, so the app's 99% has no figure from a source beside it.1 The sources read give no duration of effect in hours, and the app's 6-hour duration has no figure from a source beside it. The trials in the table were mostly in small groups of healthy adults, and Grgic and colleagues note that "Most individual studies included in the published meta-analyses were conducted among young men".11 Lara and colleagues could not say whether tolerance would deepen after 20 days, and Drake and colleagues could not draw conclusions about tolerance from intermittent dosing.9,8 Plasma caffeine concentrations were not measured in the Drake or Lara trials, so those sleep and tolerance results are not tied to individual levels.8,9 Trexler and colleagues compared caffeine anhydrous with coffee in one session of strength and sprint tests, and that comparison is a single trial in the sources read.7 A European Food Safety Authority opinion on caffeine could not be retrieved and is not among the sources read.

What is the half-life of caffeine anhydrous?

Reviews give caffeine's elimination half-life as 2.5 to 10 hours, and the app lists about 5.5 hours.1 A second review gives a range of 2 to 12 hours.4 Kaplan and colleagues reported a longer elimination half-life at 500 mg than at 250 mg.6

How long does caffeine take to reach its peak level?

Cappelletti and colleagues give the maximum plasma concentration as reached after 30 to 60 minutes, and the app lists about 0.75 hours (45 minutes).4 The same review notes reports between 15 and 120 minutes.4

Is caffeine banned by WADA?

No: the 2026 WADA Prohibited List places caffeine in the 2026 Monitoring Program and says those substances are not considered Prohibited Substances.14

Which enzyme breaks down caffeine?

CYP1A2 is the main enzyme, accounting for about 95% of caffeine clearance in one review.4 Nehlig describes the pharmacokinetics of caffeine as highly variable among individuals because of a polymorphism at CYP1A2.5

Is caffeine anhydrous stronger than coffee?

In one trial of 54 resistance-trained males, caffeine anhydrous did not improve performance more than caffeine-matched coffee.7 Leg press one-repetition maximum improved more with coffee than with caffeine anhydrous (p = .04).7

Does tolerance to caffeine develop?

In an 11-person crossover trial, the performance effect of 3 mg/kg/day was largest on day 1 and progressively decreased over 20 days.9 The authors also report small-to-moderate improvements still present after 20 days.9 Watson and colleagues concluded that "tolerance is incomplete" for peripheral and central effects after a week of regular dosing.10 They also write that tolerance was not demonstrated in performance or in improvements in positive aspects of mood.10 The app's notes give about 2 weeks for tolerance to build; Lara and colleagues report a continued ergogenic effect for 15-18 days, with the effect highest on the first day and then progressively decreasing.9

Does caffeine taken hours before bed affect sleep?

In Drake and colleagues' 12-person home study, 400 mg of caffeine 6 hours before bedtime lowered objectively measured total sleep time by 1.1 to 1.2 hours against placebo.8 The sleep diary showed a 41 minute fall in total sleep time at 6 hours that approached significance (p = 0.08), and the study was funded by an investigator-initiated grant from Zeo Inc.8 The pooled analysis of 24 studies found caffeine reduced total sleep time by 45 minutes.12

Does caffeine improve exercise performance?

An umbrella review of 21 meta-analyses found caffeine was ergogenic for aerobic endurance, muscle strength, muscle endurance, power, jumping performance and exercise speed.11 The authors add that not all analyses gave a definite direction on the 95% prediction interval.11 They grade the quality of evidence as generally moderate with some low to very low, and note that most individual studies were conducted among young men.11

Does the FDA give a daily limit for caffeine?

The FDA has cited 400 milligrams a day for most adults as an amount not generally associated with negative effects.3 The same page says sensitivity and the speed of elimination vary widely between people.3

12

References

  1. Magkos F, Kavouras SA. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. Crit Rev Food Sci Nutr 2005. PMID 16371327
  2. Spirit Pharmaceuticals LLC. Stay Awake (caffeine 200 mg tablets). US over-the-counter Drug Facts label, DailyMed record version 5, 13 December 2024. DailyMed label
  3. US Food and Drug Administration. Spilling the Beans: How Much Caffeine is Too Much? Consumer Update, content current as of 28 August 2024. FDA consumer update
  4. Cappelletti S, Piacentino D, Sani G, Aromatario M. Caffeine: cognitive and physical performance enhancer or psychoactive drug? Curr Neuropharmacol 2015. PMID 26074744
  5. Nehlig A. Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption. Pharmacol Rev 2018. PMID 29514871
  6. Kaplan GB, Greenblatt DJ, Ehrenberg BL, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 1997. PMID 9378841
  7. Trexler ET, Smith-Ryan AE, Roelofs EJ, Hirsch KR, Mock MG. Effects of coffee and caffeine anhydrous on strength and sprint performance. Eur J Sport Sci 2016. PMID 26394649
  8. Drake C, Roehrs T, Shambroom J, Roth T. Caffeine effects on sleep taken 0, 3, or 6 hours before going to bed. J Clin Sleep Med 2013. PMID 24235903
  9. Lara B, Ruiz-Moreno C, Salinero JJ, Del Coso J. Time course of tolerance to the performance benefits of caffeine. PLoS One 2019. PMID 30673725
  10. Watson J, Deary I, Kerr D. Central and peripheral effects of sustained caffeine use: tolerance is incomplete. Br J Clin Pharmacol 2002. PMID 12392588
  11. Grgic J, Grgic I, Pickering C, Schoenfeld BJ, Bishop DJ, Pedisic Z. Wake up and smell the coffee: caffeine supplementation and exercise performance, an umbrella review of 21 published meta-analyses. Br J Sports Med 2020. PMID 30926628
  12. Gardiner C, Weakley J, Burke LM, et al. The effect of caffeine on subsequent sleep: A systematic review and meta-analysis. Sleep Med Rev 2023. PMID 36870101
  13. Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol 2017. PMID 28438661
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list